0001123292-16-002600.txt : 20160817
0001123292-16-002600.hdr.sgml : 20160817
20160817141924
ACCESSION NUMBER: 0001123292-16-002600
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150805
FILED AS OF DATE: 20160817
DATE AS OF CHANGE: 20160817
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zynerba Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001621443
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260389433
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 W. LANCASTER AVENUE
STREET 2: SUITE 300
CITY: DEVON
STATE: PA
ZIP: 19333
BUSINESS PHONE: 484-581-7505
MAIL ADDRESS:
STREET 1: 80 W. LANCASTER AVENUE
STREET 2: SUITE 300
CITY: DEVON
STATE: PA
ZIP: 19333
FORMER COMPANY:
FORMER CONFORMED NAME: Zynerba Pharmeceuticals, Inc.
DATE OF NAME CHANGE: 20141003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hanlon Suzanne M.
CENTRAL INDEX KEY: 0001631682
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37526
FILM NUMBER: 161838262
MAIL ADDRESS:
STREET 1: C/O ZYNERBA PHARMACEUTICALS, INC.
STREET 2: 170 N. RADNOR-CHESTER RD
CITY: RADNOR
STATE: PA
ZIP: 19087
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-08-05
0001621443
Zynerba Pharmaceuticals, Inc.
ZYNE
0001631682
Hanlon Suzanne M.
C/O ZYNERBA PHARMACEUTICALS, INC
80 W. LANCASTER AVENUE, SUITE 300
DEVON
PA
19333
0
1
0
0
Sec, General Counsel & VP HR
Common Stock
2015-08-05
4
P
0
3000
17.92
A
3000
I
By spouse
Common Stock
2016-08-16
4
S
0
3000
10.53
D
0
I
By spouse
Common Stock
39893
D
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.47 to $10.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
/s/ Suzanne M. Hanlon
2016-08-17